Sentinus, LLC Northwest Biotherapeutics Inc Transaction History

Sentinus, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$0.42 - $0.55 $5,428 - $7,108	12,925 New	12,925 $5,000
Q2 2023 Aug 14, 2023	BUY	$0.49 - $0.73 $136,710 - $203,670	279,000 Added 12.74%	2,469,440 $1.41 Million
Q1 2023 May 15, 2023	BUY	$0.58 - $0.76 $229,476 - $300,694	395,650 Added 22.04%	2,190,440 $1.38 Million
Q4 2022 Feb 15, 2023	BUY	$0.66 - $1.15 $396,247 - $690,431	600,375 Added 50.27%	1,794,790 $1.4 Million
Q3 2022 Nov 16, 2022	BUY	$0.62 - $0.81 $740,537 - $967,476	1,194,415 New	1,194,415 $1.02 Million

674K

Ticker NWBO
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 1,037,230,016
Market Cap $270M
Description
Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, wh...

Get notified when there are updates to the investment portfolio of Sentinus, LLC, based on Form 13F filings with the SEC.

Stay updated on Sentinus, LLC with notifications on news.